Kaslow Sarah R, Hani Leena, Sacks Greg D, Lee Ann Y, Berman Russell S, Correa-Gallego Camilo
Department of Surgery, NYU Grossman School of Medicine, New York, NY, USA.
Ann Surg Oncol. 2023 Jan;30(1):300-308. doi: 10.1245/s10434-022-12549-2. Epub 2022 Sep 19.
Adherence to evidence-based guidelines for gastric cancer is low, particularly at the hospital level, despite a strong association with improved overall survival (OS). We aimed to evaluate patterns of hospital and regional adherence to National Comprehensive Cancer Network guidelines for gastric cancer.
Using the National Cancer Database (2004-2015), we identified patients with stage I-III gastric cancer. Hospital-level guideline adherence was calculated by dividing the patients who received guideline adherent care by the total patients treated at that hospital. OS was estimated for each hospital. Associations between adherence, region, and survival were compared using mixed-effects, hierarchical regression.
Among 576 hospitals, the median hospital guideline adherence rate was 25% (range 0-76%) and varied significantly by region (p = 0.001). Adherence was highest in the Middle Atlantic (29%) and lowest in the East South Central region (19%); hospitals in the New England, Middle Atlantic, and East North Central regions were more likely to be guideline adherent than those in the East South Central region (all p < 0.05), after adjusting for patient and hospital mix. Most (35%) of the adherence variation was attributable to the hospital. Median 2-year OS varied significantly by region. After adjusting for hospital and patient mix, hazard of mortality was 17% lower in the Middle Atlantic (hazard ratio 0.82, 95% confidence interval 0.74-0.90) relative to the East South Central region, with most of the variation (54%) attributable to patient-level factors.
Hospital-level guideline adherence for gastric cancer demonstrated significant regional variation and was associated with longer OS, suggesting that efforts to improve guideline adherence should be directed toward lower-performing hospitals.
尽管遵循基于证据的胃癌治疗指南与改善总生存期(OS)密切相关,但在医院层面,遵循率仍然很低。我们旨在评估医院和地区层面遵循美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)胃癌治疗指南的模式。
利用国家癌症数据库(2004 - 2015年),我们确定了I - III期胃癌患者。医院层面的指南遵循率通过接受指南依从性治疗的患者数除以该医院治疗的总患者数来计算。对每家医院的总生存期进行了估计。使用混合效应分层回归比较了遵循率、地区和生存率之间的关联。
在576家医院中,医院指南遵循率的中位数为25%(范围0 - 76%),且地区差异显著(p = 0.001)。遵循率在中大西洋地区最高(29%),在东中南部地区最低(19%);在调整患者和医院构成后,新英格兰、中大西洋和东中北部地区的医院比东中南部地区的医院更有可能遵循指南(所有p < 0.05)。大部分(35%)的遵循率差异可归因于医院。2年总生存期的中位数因地区而异。在调整医院和患者构成后,相对于东中南部地区,中大西洋地区的死亡风险降低了17%(风险比0.82,95%置信区间0.74 - 0.90),大部分差异(54%)可归因于患者层面的因素。
胃癌的医院层面指南遵循率存在显著的地区差异,且与更长的总生存期相关,这表明改善指南遵循率的努力应针对表现较差的医院。